MA49599A1 - Anticorps spécifiques à cd47 et pd-l1 - Google Patents
Anticorps spécifiques à cd47 et pd-l1Info
- Publication number
- MA49599A1 MA49599A1 MA49599A MA49599A MA49599A1 MA 49599 A1 MA49599 A1 MA 49599A1 MA 49599 A MA49599 A MA 49599A MA 49599 A MA49599 A MA 49599A MA 49599 A1 MA49599 A1 MA 49599A1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- relates
- antibodies specific
- antibody
- antigen binding
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne le domaine de la biotechnologie et notamment le domaine des anticorps ou leurs fragments de liaison d'antigènes ainsi que leur utilisation. Elle concerne plus particulièrement des anticorps qui se lient spécifiquement à cd47 et pd-l1. L'invention concerne également un acide nucléique codant pour cet anticorps ou son fragment de liaison d'antigènes, un vecteur d'expression, un procédé de production d'anticorps et l'utilisation de ces anticorps et composition dans la thérapie du cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201791961A EA039662B1 (ru) | 2017-10-03 | 2017-10-03 | Антитела, специфичные к cd47 и pd-l1 |
PCT/EA2018/050001 WO2019068302A1 (fr) | 2017-10-03 | 2018-10-03 | Anticorps spécifiques à cd47 et pd-l1 |
Publications (2)
Publication Number | Publication Date |
---|---|
MA49599A1 true MA49599A1 (fr) | 2021-01-29 |
MA49599B1 MA49599B1 (fr) | 2023-05-31 |
Family
ID=65994976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA49599A MA49599B1 (fr) | 2017-10-03 | 2018-10-03 | Anticorps spécifiques à cd47 et pd-l1 |
Country Status (21)
Country | Link |
---|---|
US (1) | US11840567B2 (fr) |
EP (1) | EP3693390A4 (fr) |
JP (2) | JP2020535839A (fr) |
KR (1) | KR20200058542A (fr) |
CN (1) | CN111801352A (fr) |
AR (1) | AR113342A1 (fr) |
AU (1) | AU2018345458A1 (fr) |
BR (1) | BR112020006706A2 (fr) |
CA (1) | CA3078413A1 (fr) |
CL (1) | CL2020000919A1 (fr) |
CO (1) | CO2020004199A2 (fr) |
EA (1) | EA039662B1 (fr) |
EC (1) | ECSP20024555A (fr) |
JO (1) | JOP20200078A1 (fr) |
MA (1) | MA49599B1 (fr) |
MX (1) | MX2020004027A (fr) |
PE (1) | PE20210460A1 (fr) |
PH (1) | PH12020550214A1 (fr) |
TW (1) | TWI768129B (fr) |
WO (1) | WO2019068302A1 (fr) |
ZA (1) | ZA202002047B (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019003563A (es) | 2016-09-29 | 2019-08-12 | Beijing Hanmi Pharmaceutical Co Ltd | Construcciones de inmunoglobulina heterodimericas y metodos de preparacion de las mismas. |
JP7031810B2 (ja) | 2016-11-18 | 2022-03-08 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド | 抗pd-1/抗her2天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法 |
CN111615521A (zh) * | 2017-12-04 | 2020-09-01 | 北京韩美药品有限公司 | 抗pd-l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备 |
CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
KR20200120641A (ko) | 2018-01-15 | 2020-10-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
WO2019153200A1 (fr) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | Anticorps bispécifique de type structure d'anticorps naturel anti-pd -1/anti-her2 sous forme hétérodimère et sa préparation |
EP3564263A1 (fr) * | 2018-05-03 | 2019-11-06 | Universitätsklinikum Hamburg-Eppendorf | Protéines de fusion comprenant un vhh spécifique de marqueur de surface cellulair |
EP3969484A4 (fr) * | 2019-05-17 | 2023-07-05 | Nanjing GenScript Biotech Co., Ltd. | Protéines liant plusieurs antigènes anti-cd47/anti-pd-l1 et procédés d'utilisation associés |
CA3144244A1 (fr) * | 2019-06-25 | 2020-12-30 | Innovent Biologics (Suzhou) Co., Ltd. | Preparations contenant un anticorps bispecifique anti-cd47/pd-l1, procede de preparation associe et leur utilisation |
WO2021004480A1 (fr) * | 2019-07-08 | 2021-01-14 | 南京金斯瑞生物科技有限公司 | Anticorps bispécifique anti-cd47/anti-pd-1, son procédé de préparation et son utilisation |
KR20220070249A (ko) * | 2019-09-27 | 2022-05-30 | 베이징 스타맵 바이오메드 테크놀로지 리미티드 | 단일특이적 및 다중특이적 항체 |
CN112745392B (zh) * | 2019-10-30 | 2022-07-01 | 上海洛启生物医药技术有限公司 | 抗pd-l1/cd47双特异性抗体及其用途 |
IL293926A (en) * | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies unique to d47, pd-l1 and their uses |
CN115315445B (zh) * | 2020-02-12 | 2024-07-12 | 上海诗健生物科技有限公司 | 一种靶向人cd47的单域抗体及其用途 |
WO2022057939A1 (fr) * | 2020-09-21 | 2022-03-24 | I-Mab Biopharma Co., Ltd. | Composition pharmaceutique comprenant un anticorps cd47 et un inhibiteur de pd-1/pd-l1 |
WO2022095970A1 (fr) * | 2020-11-06 | 2022-05-12 | 百奥泰生物制药股份有限公司 | Anticorps bispécifique et son utilisation |
US20230406921A1 (en) * | 2020-11-12 | 2023-12-21 | Mabwell (shanghai) Bioscience Co., Ltd. | Antibody and preparation method therefor |
AU2022222994A1 (en) * | 2021-02-19 | 2023-09-28 | Seoul National University R&Db Foundation | Single domain antibody against cd47 and use thereof |
EP4296283A1 (fr) * | 2021-02-19 | 2023-12-27 | SHAPERON Inc. | Anticorps à domaine unique dirigé contre pd-l1 et son utilisation |
CN116917322A (zh) * | 2021-02-19 | 2023-10-20 | 沙裴隆有限公司 | 针对pd-l1及cd47的双特异性单域抗体及其用途 |
CA3219221A1 (fr) * | 2021-05-07 | 2022-11-10 | Immuneoncia Therapeutics, Inc. | Anticorps bispecifique se liant specifiquement a cd47 et pd-l1 |
EP4359445A1 (fr) * | 2021-06-21 | 2024-05-01 | Joint Stock Company "Biocad" | Anticorps bispécifique isolé se liant de mani7re spécifique à cd47 et pd-l1 |
CN115702931A (zh) * | 2021-08-06 | 2023-02-17 | 百奥泰生物制药股份有限公司 | 抗pd-l1/cd47双特异抗体在治疗疾病中的应用 |
CN118076644A (zh) * | 2021-09-30 | 2024-05-24 | 正大天晴药业集团股份有限公司 | 针对免疫检查点的双特异性抗体 |
WO2023154730A2 (fr) * | 2022-02-09 | 2023-08-17 | Exelixis, Inc. | Agents de liaison multispécifiques et leurs utilisations |
WO2023224412A1 (fr) * | 2022-05-19 | 2023-11-23 | (주)샤페론 | Anticorps bispécifique à domaine unique humanisé dirigé contre pd-l1 et cd47 et son utilisation |
WO2024022384A1 (fr) * | 2022-07-28 | 2024-02-01 | Shenzhen Enduring Biotech , Ltd. | Conjugué anticorps-médicament bispécifique anti-cd47/anti-pd-l1 à base de peg |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
EP0739904A1 (fr) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Réactifs bispécifiques pour le traitement du SIDA |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
WO1992000373A1 (fr) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Production de melanines a l'aide de microorganismes transformes |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
CA2103059C (fr) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Methode de production d'anticorps humanises |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
CA2129663C (fr) | 1992-02-06 | 2005-07-05 | James S. Huston | Proteine fixatrice biosynthetique pour marqueur du cancer |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
CA2226962A1 (fr) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Utilisation d'agents liants a cd47 et ces ligands pour le traitement ou prophylaxie de maladies inflammatoire, autoimmunitaire et allergique et pour le traitement de rejet de greffons |
JP4896327B2 (ja) | 1999-08-23 | 2012-03-14 | ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド | Pd−1、b7−4の受容体、およびその使用 |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
US6957551B2 (en) | 2000-08-18 | 2005-10-25 | Linde Ag | Method for producing an air separation installation |
AU2002258941A1 (en) | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
EP2262837A4 (fr) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Protéines de liaison avec pd-1 |
MX349463B (es) | 2008-09-26 | 2017-07-31 | Univ Emory | Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos. |
PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
DK2812443T3 (da) | 2012-02-06 | 2019-08-26 | Inhibrx Inc | Cd47-antistoffer og fremgangsmåder til anvendelse deraf |
CA2892585C (fr) * | 2012-12-03 | 2022-07-05 | Novimmune S.A. | Anticorps anti-cd47 et leurs procedes d'utilisation |
JP6572131B2 (ja) | 2012-12-12 | 2019-09-04 | バスキュロックス インコーポレイテッド | 治療用cd47抗体 |
GB201300706D0 (en) | 2013-01-15 | 2013-02-27 | Cancer Rec Tech Ltd | Antibody |
SG10201706383XA (en) | 2013-02-06 | 2017-09-28 | Inhibrx Lp | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
WO2016023001A1 (fr) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Agents pd-1 à haute affinité multispécifiques et procédés d'utilisation |
BR112017007379A2 (pt) * | 2014-10-14 | 2017-12-19 | Dana Farber Cancer Inst Inc | moléculas de anticorpo para pd-l1 e usos das mesmas |
GB2558131B (en) | 2015-09-21 | 2021-05-19 | Surface Oncology Inc | Anti-CD47 antibodies and methods of use |
RU2665790C1 (ru) * | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
-
2017
- 2017-10-03 EA EA201791961A patent/EA039662B1/ru unknown
-
2018
- 2018-09-28 TW TW107134503A patent/TWI768129B/zh active
- 2018-10-03 EP EP18864490.0A patent/EP3693390A4/fr active Pending
- 2018-10-03 MA MA49599A patent/MA49599B1/fr unknown
- 2018-10-03 CA CA3078413A patent/CA3078413A1/fr active Pending
- 2018-10-03 KR KR1020207012767A patent/KR20200058542A/ko active Search and Examination
- 2018-10-03 WO PCT/EA2018/050001 patent/WO2019068302A1/fr unknown
- 2018-10-03 PE PE2020000513A patent/PE20210460A1/es unknown
- 2018-10-03 AU AU2018345458A patent/AU2018345458A1/en active Pending
- 2018-10-03 CN CN201880078338.5A patent/CN111801352A/zh active Pending
- 2018-10-03 JO JOP/2020/0078A patent/JOP20200078A1/ar unknown
- 2018-10-03 MX MX2020004027A patent/MX2020004027A/es unknown
- 2018-10-03 JP JP2020519341A patent/JP2020535839A/ja active Pending
- 2018-10-03 US US16/753,587 patent/US11840567B2/en active Active
- 2018-10-03 BR BR112020006706-7A patent/BR112020006706A2/pt unknown
- 2018-10-04 AR ARP180102862A patent/AR113342A1/es unknown
-
2020
- 2020-04-03 CL CL2020000919A patent/CL2020000919A1/es unknown
- 2020-04-03 PH PH12020550214A patent/PH12020550214A1/en unknown
- 2020-04-08 CO CONC2020/0004199A patent/CO2020004199A2/es unknown
- 2020-05-04 ZA ZA2020/02047A patent/ZA202002047B/en unknown
- 2020-05-06 EC ECSENADI202024555A patent/ECSP20024555A/es unknown
-
2023
- 2023-07-07 JP JP2023112302A patent/JP2023130455A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019068302A1 (fr) | 2019-04-11 |
AU2018345458A2 (en) | 2020-05-21 |
TWI768129B (zh) | 2022-06-21 |
RU2020115122A3 (fr) | 2021-10-29 |
EA039662B1 (ru) | 2022-02-24 |
AU2018345458A1 (en) | 2020-05-14 |
US11840567B2 (en) | 2023-12-12 |
CN111801352A (zh) | 2020-10-20 |
EP3693390A1 (fr) | 2020-08-12 |
EP3693390A4 (fr) | 2021-11-03 |
MA49599B1 (fr) | 2023-05-31 |
PE20210460A1 (es) | 2021-03-08 |
PH12020550214A1 (en) | 2021-02-15 |
ECSP20024555A (es) | 2020-06-30 |
BR112020006706A2 (pt) | 2020-10-06 |
EA201791961A1 (ru) | 2019-04-30 |
AR113342A1 (es) | 2020-04-22 |
JP2020535839A (ja) | 2020-12-10 |
JP2023130455A (ja) | 2023-09-20 |
RU2020115122A (ru) | 2021-10-29 |
ZA202002047B (en) | 2022-08-31 |
CO2020004199A2 (es) | 2020-04-24 |
US20200270345A1 (en) | 2020-08-27 |
KR20200058542A (ko) | 2020-05-27 |
CL2020000919A1 (es) | 2020-10-16 |
CA3078413A1 (fr) | 2019-04-11 |
JOP20200078A1 (ar) | 2020-04-30 |
TW201922781A (zh) | 2019-06-16 |
MX2020004027A (es) | 2020-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA49599A1 (fr) | Anticorps spécifiques à cd47 et pd-l1 | |
PH12016501691A1 (en) | Antibodies to matrix metalloproteinase 9 | |
MX2018007630A (es) | Anticuerpos contra la metaloproteinasa de matriz 9. | |
PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
ZA202005259B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
MA35740B1 (fr) | Compositions et procédés pour des anticorps ciblant le facteur p | |
MA40476B1 (fr) | Anticorps et fragments de fixation à l'antigène anti-lag3 | |
MA44547A1 (fr) | Anticorps anti-pd-1,procédé de leur production et de leur utilisation | |
MX2009006891A (es) | Anticuerpos cd44. | |
MY194997A (en) | Anti-ccr7 antibody drug conjugates | |
MA54969A1 (fr) | Anticorps monoclonal se liant spécifiquement à gitr | |
EA201101516A1 (ru) | Антитела, специфические для кадгерина-17 | |
MA47221A1 (fr) | Anticorps monoclonal à pd-l1 | |
MX2017004117A (es) | Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171). | |
MA39378A1 (fr) | Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer | |
WO2021227307A8 (fr) | Anticorps anti-cd73 et son utilisation | |
BR112021017801A2 (pt) | Anticorpos biespecíficos anti-vbeta17/anti-cd123 | |
JOP20210159A1 (ar) | أجسام مضادة لـ pmel17 ومترافقات منها | |
MA44207B1 (fr) | Immunoglobulines conjuguées cys80 | |
MA45831B1 (fr) | Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation | |
MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. | |
MA49607A1 (fr) | Anticorps monoclonal pour il-5ra | |
EA202092672A1 (ru) | Антитела против dll3 и их применения | |
MA41666B1 (fr) | Anticorps anti-ox40 et leurs utilisations |